Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice
- 1 September 2014
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (13) , 2303-2308
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end pointsAnnals of Oncology, 2011
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007JNCI: Journal of the National Cancer Institute, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?Annals of Oncology, 2005
- Cancer patients’ attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision supportPatient Education and Counseling, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Reporting results of cancer treatmentCancer, 1981
- Assessment of response to therapy in advanced breast cancerBritish Journal of Cancer, 1977
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960